Pikuła Agnieszka, Skórzewska Magdalena, Pelc Zuzanna, Mlak Radosław, Gęca Katarzyna, Sędłak Katarzyna, Ciseł Bogumiła, Kwietniewska Magdalena, Rawicz-Pruszyński Karol, Polkowski Wojciech P
Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, Poland.
Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11 St., 20-080 Lublin, Poland.
Cancers (Basel). 2022 Apr 14;14(8):1997. doi: 10.3390/cancers14081997.
The prognostic value of the systemic inflammatory response markers, namely neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) has not yet been clarified in patients undergoing neoadjuvant chemotherapy (NAC) and gastrectomy for advanced gastric cancer (GC) in the Eastern European population. This study aimed to verify the prognostic value of NLR, PLR, and LMR in GC patients undergoing multimodal treatment. One hundred six GC patients undergoing NAC and gastrectomy between 2012 and 2020 were included. Analysed blood samples were obtained prior to NAC (pre-NAC group) and before surgical treatment (post-NAC group). To evaluate the prognostic value of the NLR, LMR, and PLR, univariable and multivariable overall survival (OS) analyses were performed. In the pre-NAC group, elevated NLR and PLR were associated with significantly higher risk of death (mOS: 36 vs. 87 months; HR = 2.21; = 0.0255 and mOS: 30 vs. 87 months; HR = 2.89; = 0.0034, respectively). Additionally, a significantly higher risk of death was observed in patients with elevated NLR in the post-NAC group (mOS: 35 vs. 87 months; HR = 1.94; = 0.0368). Selected systemic inflammatory response markers (NLR, PLR) are significant prognostic factors in patients with advanced GC treated with NAC and gastrectomy, as shown in the Eastern European population.
在东欧人群中，全身炎症反应标志物，即中性粒细胞与淋巴细胞比值（NLR）、淋巴细胞与单核细胞比值（LMR）和血小板与淋巴细胞比值（PLR），在接受新辅助化疗（NAC）和胃癌根治术的晚期胃癌（GC）患者中的预后价值尚未明确。本研究旨在验证NLR、PLR和LMR在接受多模式治疗的GC患者中的预后价值。纳入了2012年至2020年间106例接受NAC和胃癌根治术的GC患者。分析的血样在NAC之前（NAC前组）和手术治疗之前（NAC后组）采集。为了评估NLR、LMR和PLR的预后价值，进行了单变量和多变量总生存（OS）分析。在NAC前组中，NLR和PLR升高与死亡风险显著升高相关（中位总生存期：36个月对87个月；风险比=2.21；P=0.0255和中位总生存期：30个月对87个月；风险比=2.89；P=0.0034）。此外，在NAC后组中，NLR升高的患者观察到显著更高的死亡风险（中位总生存期：35个月对87个月；风险比=1.94；P=0.0368）。如东欧人群所示，选定的全身炎症反应标志物（NLR、PLR）是接受NAC和胃癌根治术的晚期GC患者的重要预后因素。
